Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.46 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14412223 | 0.87 | NMT1 (0.52) | NMT1BRD4RIPK2KDM4ECASP1 | |
| SCHEMBL12759448 | 0.84 | TGFBR1 (0.48) | NMT1ALDH1A1MEN1POLBBRD4 | |
| SCHEMBL17264894 | 0.82 | NMT1 (0.52) | NMT1BRD4RIPK2KDM4ECASP1 | |
| SCHEMBL31398200 | 0.82 | LPO (0.39) | NMT1ALDH1A1BRD4RIPK2TSHR | |
| SCHEMBL31319136 | 0.80 | MAP4K4 (0.41) | MAP4K4BRD4 | |
| SCHEMBL12320076 | 0.79 | KDR (0.47) | NMT1ALDH1A1MEN1POLBBRD4 | |
| SCHEMBL3488664 | 0.79 | IDO1 (0.49) | NMT1ALDH1A1MEN1POLBBRD4 | |
| SCHEMBL28469346 | 0.79 | NMT1 (0.44) | NMT1BRD4RIPK2KDM4ECASP1 | |
| SCHEMBL29711750 | 0.79 | HSD17B2 (0.48) | NMT1TNK2RIPK2 | |
| SCHEMBL3489826 | 0.79 | NMT1 (0.47) | NMT1ALDH1A1MEN1BRD4RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138961-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2024137813-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3319955-B1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2019161495-A9 | RIPK2 INHIBITORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019161495-A1 | RIPK2 INHIBITORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-08-29 | — | — | WO | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20060205721-A1 | 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents | PARAGON INTELLECTUAL PROPERTIES, LLC | 2006-09-14 | — | — | US | disclosed |
| US-20060183747-A1 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
| EP-1658292-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | US | disclosed |
| WO-2005012307-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012304-A2 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1442024-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037877-A1 | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
| US-6043254-A | ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-28 | — | — | US | disclosed |
| WO-1999051590-A1 | SUBSTITUTED INDOLINONES AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183747-A1 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | GSK3B, GSK3A, GRK3 | MAP4K4 626/4885NMT1 641/4885ALDH1A1 3943/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAP4K4 186/4885NMT1 2643/4885ALDH1A1 4333/4885 |
| US-20060205721-A1 | 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents | PSEN1, CHRNA3, CHRNA6 | MAP4K4 3716/4885NMT1 1692/4885ALDH1A1 1609/4885 |
| US-20060063789-A1 | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | GSK3B, GSK3A, PHKG1 | MAP4K4 1428/4885NMT1 525/4885ALDH1A1 3571/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAP4K4 169/4885NMT1 2817/4885ALDH1A1 4184/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAP4K4 169/4885NMT1 2817/4885ALDH1A1 4184/4885 |
| US-20260138961-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | POLRMT, TFAM, UQCRC1 | MAP4K4 2943/4885NMT1 2601/4885ALDH1A1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.